Pfizer Inc. (NYSE:PFE) is included among the 14 Low PE High Dividend Stocks to Buy Right Now. On March 6, Reuters reported that China has approved Pfizer Inc. (NYSE:PFE)’s GLP-1 treatment Xianweiying ...
By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...
Pfizer China announced that the National Medical Products Administration (NMPA) has officially approved the new-generation ...
China has approved Pfizer's GLP-1 drug Xianweiying for long-term weight management in overweight or obese adults, the U.S. drugmaker said ...
China's National Medical Products Administration has approved Pfizer Inc.’s PFE ecnoglutide injection for chronic weight management in adults with overweight or obesity, marking the first approval of ...
Hangzhou Sciwind Biosciences Co., Ltd. (Sciwind Biosciences) today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation ...
Pfizer receives a tactical upgrade to Hold following its acquisition of Metsera, re-entering the obesity/GLP-1 market with promising clinical assets. The Metsera deal offers PFE strategic optionality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results